A helpful biotech starter pack needs one regulatory process guide, one translational science lens, and one open computational toolkit people can actually learn from. That mix reminds the team that evidence, operations, and computation all need owners.
The kinds of materials worth saving in this space:
- primary literature with clear translational implications
- trial operations checklists and startup timelines
- regulatory guidance mapped to actual development choices
Read:
- FDA drug development and approval process: fda.gov/drugs/development-approval-process-drugs
A grounding document for the path from development to review and approval.
- NCATS translational science spectrum: ncats.nih.gov/translation/spectrum
Useful for keeping research work tied to concrete translational stages.
- scverse: scverse.org/
A strong starting point for open computational work in modern omics analysis.
Documents and downloadable guides:
- Addgene protocols: addgene.org/protocols/
Practical wet-lab documentation that is genuinely useful for day-to-day work.
- NCBI Bookshelf: ncbi.nlm.nih.gov/books/
A deep public archive for primers, reference texts, and method overviews.
Watch:
- NIH video archive: youtube.com/@NIH/videos
Webinars and talks that help keep the science connected to real public research practice.
- Addgene video archive: youtube.com/@addgene/videos
Clear explainers and protocols from a source readers already trust for plasmid work.
Build or inspect:
- scvi-tools: github.com/scverse/scvi-tools
Open source probabilistic tooling for single-cell and spatial omics work.
- Biopython: github.com/biopython/biopython
Still useful as a practical reminder that a lot of bio tooling is public and inspectable.
Image references:
- Addgene protocol visuals: addgene.org/protocols/
Bench-ready diagrams and step images that make the written protocols more legible.
Keep Exploring
Jump to the author, the parent community or folio, and a few closely related posts.
Related Posts
A pre-scale review for biotech before expanding the scope
Before scaling a biotech strategy, I want to see a legible evidence chain, a realistic operational plan for the next study or assay expansion, and a regulatory ...
TopicFolio Research in Biotech Operating Notes · 0 likes · 0 comments
Three live arguments in biotech that are worth having in public
The central debates are about how much platform optionality to preserve, when to narrow around a lead program, and what evidence threshold deserves clinical acc...
Nina Patel in Biotech Operating Notes · 0 likes · 0 comments
The quiet mistakes that slow people down in biotech
The classic mistake is overselling platform breadth before the lead program has earned it. Another is treating regulatory strategy like a writing exercise that ...
TopicFolio Editorial in Biotech Operating Notes · 0 likes · 0 comments
Explore more organized conversations on TopicFolio.